Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – Stock analysts at William Blair cut their FY2017 earnings per share (EPS) estimates for Achillion Pharmaceuticals in a report released on Wednesday. William Blair analyst Y. Xu now expects that the biopharmaceutical company will post earnings of ($0.70) per share for the year, down from their prior forecast of ($0.68). William Blair also issued estimates for Achillion Pharmaceuticals’ FY2018 earnings at ($0.82) EPS and FY2019 earnings at $0.08 EPS.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same quarter in the prior year, the firm posted ($0.14) earnings per share.

COPYRIGHT VIOLATION WARNING: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/11/william-blair-weighs-in-on-achillion-pharmaceuticals-inc-s-fy2017-earnings-achn.html.

A number of other research analysts have also issued reports on the stock. Robert W. Baird increased their target price on shares of Achillion Pharmaceuticals from $5.00 to $10.00 and gave the stock an “outperform” rating in a research report on Monday, April 24th. Leerink Swann upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $4.00 to $6.00 in a research report on Thursday, May 18th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. BidaskClub lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th. Finally, Jefferies Group LLC restated a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Achillion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.25.

Achillion Pharmaceuticals (NASDAQ ACHN) remained flat at $4.43 on Friday. 395,507 shares of the company traded hands. The stock’s market cap is $605.85 million. Achillion Pharmaceuticals has a 12 month low of $3.15 and a 12 month high of $9.49. The stock has a 50-day moving average of $4.37 and a 200-day moving average of $4.12.

A number of institutional investors have recently modified their holdings of ACHN. Cambridge Investment Research Advisors Inc. increased its position in shares of Achillion Pharmaceuticals by 3.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 800 shares during the last quarter. Deschutes Portfolio Strategy LLC increased its position in shares of Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 3,000 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 4,144 shares during the last quarter. TradeLink Capital LLC bought a new position in shares of Achillion Pharmaceuticals during the second quarter valued at approximately $132,000. Finally, Teza Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals during the first quarter valued at approximately $131,000. 70.83% of the stock is owned by institutional investors and hedge funds.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.